baicalin has been researched along with oxidopamine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, Y; Gao, J; Kang, C; Kang, M; Liu, X; Wang, L | 1 |
| Chen, G; Kang, Z; Ma, J; Zhai, H; Zhang, H | 1 |
2 other study(ies) available for baicalin and oxidopamine
| Article | Year |
|---|---|
Baicalin alleviates 6-hydroxydopamine-induced neurotoxicity in PC12 cells by down-regulation of microRNA-192-5p.
Topics: Animals; Apoptosis; Autophagy; Cell Survival; Flavonoids; MicroRNAs; Neurotoxicity Syndromes; Oxidopamine; Parkinson Disease; PC12 Cells; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-mdm2; Rats; Signal Transduction; Tumor Suppressor Protein p53 | 2019 |
Baicalin attenuated substantia nigra neuronal apoptosis in Parkinson's disease rats via the mTOR/AKT/GSK-3β pathway.
Topics: Animals; Apoptosis; Behavior, Animal; Disease Models, Animal; Female; Flavonoids; Glycogen Synthase Kinase 3 beta; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Signal Transduction; Substantia Nigra; TOR Serine-Threonine Kinases | 2019 |